Prnewswire Inxmed Co Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

InxMed Reports Positive Phase Ib/II Results for Ifebemtinib in Combination with Garsorasib in Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation

/PRNewswire/ InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against tumor-treatment resistance and metastasis,.

United statesJames mcleodPrnewswire inxmed co ltdChina national medical products administrationUniversity chinese academy of sciencesDrug administrationAmerican society of clinical oncologyClinical oncologyAnnual meetingZhengbo songAssociate professorZhejiang cancer hospitalUniversity chinese academyPrincipal studyChief medical officerBreakthrough therapy designation

InxMed Releases Data Demonstrating Ifebemtinib (IN10018) Trending Toward Survival Benefit at ESMO 2023

InxMed Releases Data Demonstrating Ifebemtinib (IN10018) Trending Toward Survival Benefit at ESMO 2023
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesEuropean society for medical oncologyInxmed co ltdDrug administrationPrnewswire inxmed co ltdChina national medical products administrationMed releases data demonstrating ifebemtinibTrending toward survival benefitMedical oncologyResistant recurrent ovarianObjective response rateProgression free survivalOverall survivalDisease control rateNegative breast cancerDrug application

InxMed Presents New Data at 14th Annual World ADC Highlighting Synergy of IN10018 with ADCs and Novel Stroma targeting pipeline

/PRNewswire/ InxMed Co., Ltd, a clinical-stage biotechnology company dedicated on developing innovative therapies to overcome treatment resistance for.

San diegoUnited statesZaiqi wangPrnewswire inxmed co ltdInxmed co ltdAnnual worldChief executive officerInxmed coHealth care amp hospitalsMedical pharmaceuticalsTrade show newsClinical trials amp medical discoveries

InxMed Announces First Patient Dosed in Phase 2 Pivotal Study of IN10018 In Patients with Platinum-Resistant Recurrent Ovarian Cancer

/PRNewswire/ InxMed Co., Ltd, a clinical-stage biotechnology company dedicates to developing innovative therapies targeting drug resistance and metastasis.

China national medical products administrationPrnewswire inxmed co ltdDrug administrationTypeb meetingInxmed co

InxMed IN10018 at ASCO 2022 demonstrates robust efficacy in patients with platinum-resistant recurrent ovarian cancer

NANJING, China, May 29, 2022 /PRNewswire/ InxMed Co., Ltd, a clinical-stage biotechnology company dedicates on developing innovative therapies.

United statesZaiqi wangChina national medical products administrationPrnewswire inxmed co ltdAmerican society of clinical oncologyBoehringer ingelheimDrug administrationAmerican societyClinical oncology